tbuckley/cabot-search huggingface dataset:
miR‐210 Participates in Hepatic Ischemia Reperfusion Injury by Forming a Negative Feedback Loop With SMAD4
Authors: Wen‐Ming Pan, Hui Wang, Xiao‐Fei Zhang, Peng Xu, Guo‐Liang Wang, Yi‐Jing Li, Kun‐Peng Huang, Yun‐Wei Zhang, Huan Zhao, Run‐Lei Du, Hai Huang, Xiao‐Dong Zhang, Jin‐Xiang Zhang
Journal: Hepatology (2020)

Background and Aims Hepatic ischemia‐reperfusion (IR) injury is a major complication of liver transplantation, resection, and hemorrhagic shock. Hypoxia is a key pathological event associated with IR injury. MicroRNA‐210 (miR‐210) has been characterized as a micromanager of hypoxia pathway. However, its function and mechanism in hepatic IR injury is unknown. Approach and Results In this study, we found miR‐210 was induced in liver tissues from patients subjected to IR‐related surgeries. In a murine model of hepatic IR, the level of miR‐210 was increased in hepatocytes but not in nonparenchymal cells. miR‐210 deficiency remarkably alleviated liver injury, cell inflammatory responses, and cell death in a mouse hepatic IR model. In vitro, inhibition of miR‐210 decreased hypoxia/reoxygenation (HR)–induced cell apoptosis of primary hepatocytes and LO2 cells, whereas overexpression of miR‐210 increased cells apoptosis during HR. Mechanistically, miR‐210 directly suppressed mothers against decapentaplegic homolog 4 (SMAD4) expression under normoxia and hypoxia condition by directly binding to the 3′ UTR of SMAD4. The pro‐apoptotic effect of miR‐210 was alleviated by SMAD4, whereas short hairpin SMAD4 abrogated the anti‐apoptotic role of miR‐210 inhibition in primary hepatocytes. Further studies demonstrated that hypoxia‐induced SMAD4 transported into nucleus, in which SMAD4 directly bound to the promoter of miR‐210 and transcriptionally induced miR‐210, thus forming a negative feedback loop with miR‐210. Conclusions Our study implicates a crucial role of miR‐210‐SMAD4 interaction in hepatic IR‐induced cell death and provides a promising therapeutic approach for liver IR injury.
A circulating epithelial cell type merging stem cell, EMT, and hypoxic stress markers in early and advanced breast cancer.
Authors: Leo Habets, Wolfgang Koerber, Bettina Frenken, Ilham El Ghali, Mahmoud Danaei, Manfred Kusche, Uwe Peisker, Torsten Kroll, Katharina Pachmann
Journal: Journal of Clinical Oncology (2012)

10600 Background: MAINTRAC as developed by our coworkers from Jena finds more CETC. They found CETC in 90% of high risk patients. Circulating cells in epithelial mesenchymal transition (EMT+) should be detectable in early disease. Methods: 2 colours (7AAD, EP-FITC) detected living and dead cells. Cells in EMT (EP-FITC, Vim-PE) were analysed in paralell. Complex marker expression urged us to introduce a three colour technique. 1. EPCAM-FITC, Vimentin-PE and DAPI , marking living or dead cells in EMT. 2. EP-FITC, Vim-PE and CD44 PB for stemness. ACA9 (hypoxia) and PARP-1 expression (genotox) were used too. Results: In the 2 colour phase we examined CEC in 110 patients with early disease and 44 patients with metastasis. Cells were detectable in both disease situations in 50 and 60% of patients, in a control population only in few patients low numbers were found. In non cancer situations e.g liver disease high numbers of EMT+cells were found.The results of 3 colour analysis are shown in the table. No clear differences between the classical risk groups are found, other subgroups are too small yet to be considered. Conclusions: Our findings show that in both disease situations cells merging EMT, stemcells ( EP+,Vim+.CD44+) and other markers are detectable. This cell type however is found also in non cancer conditions.We hypothesize that hypoxia is the common driver. Metastasis gives different patterns. Highly aggressive cancers show often none or few cells. In less agressive disease high cell numbers are found. We need to characterize the "benign" EMT phenomenon, as it could mingle with "real" CTC. Definitely liver is the source of these benign cells. Multi colour analysis will reveal the differences. Nevertheless monitoring of this special cell type could give new insights in the metastatic process in early and late disease. [Table: see text]
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Authors: Sangwoo S. Kim, Sarek Shen, Sayuri Miyauchi, P. Dominick Sanders, Ida Franiak-Pietryga, Loren Mell, J. Silvio Gutkind, Ezra E.W. Cohen, Joseph A. Califano, Andrew B. Sharabi
Journal: Clinical Cancer Research (2020)

Abstract Purpose: To characterize the role of B cells on human papilloma virus (HPV)-associated cancer patient outcomes and determine the effects of radiation and PD-1 blockade on B-cell populations. Experimental Design: Tumor RNA-sequencing data from over 800 patients with head and neck squamous cell carcinoma (HNSCC) and cervical cancer, including a prospective validation cohort, was analyzed to study the impact of B-cell gene expression on overall survival (OS). A novel murine model of HPV+ HNSCC was used to study the effects of PD-1 blockade and radiotherapy on B-cell activation, differentiation, and clonality including analysis by single-cell RNA-sequencing and B-cell receptor (BCR)-sequencing. Human protein microarray was then used to quantify B-cell–mediated IgG and IgM antibodies to over 16,000 proteins in the serum of patients treated on a clinical trial with PD-1 blockade. Results: RNA-sequencing identified CD19 and IGJ as novel B-cell prognostic biomarkers for 3-year OS (HR, 0.545; P &amp;lt; 0.001). PD-1 blockade and radiotherapy enhance development of memory B cells, plasma cells, and antigen-specific B cells. BCR-sequencing found that radiotherapy enhances B-cell clonality, decreases CDR3 length, and induces B-cell somatic hypermutation. Single-cell RNA-sequencing identified dramatic increases in B-cell germinal center formation after PD-1 blockade and radiotherapy. Human proteome array revealed enhanced IgG and IgM antibody responses in patients who derived clinical benefit but not those with progressive disease after treatment with PD-1 blockade. Conclusions: These findings establish a key role for B cells in patient outcomes and responses to PD-1 blockade in HPV-associated squamous cell carcinomas and demonstrate the need for additional diagnostics and therapeutics targeting B cells.
CORONARY ARTERY CALCIUM (CAC) AND GENOMIC RISK SCORES (GRS): ANALYTICAL APPROACH OF PILOT STUDY BASED CARDIOVASCULAR RISK
Authors: Bhanu Chaganti, April Kinninger, Lavanya Cherukuri, Divya Birudaraju, Sajad Hamal, Ferdinand Flores, Christopher Dailing, Sarvanan Krishnamoorthy, Robert Trine, Greg Gibson, Matthew J. Budoff
Journal: Journal of the American College of Cardiology (2020)
PRE- VS POST-PROCEDURE MITRAL VALVE AREA AND MEAN DIASTOLIC GRADIENT IN PATIENTS WITH SECONDARY MITRAL REGURGITATION UNDERGOING EDGE-TO-EDGE MITRAL VALVE REPAIR
Authors: Didem Oguz, Ratnasari Padang, Sorin Pislaru, Vuyisile Tlhopane Nkomo, Sunil V. Mankad, Youssef Maalouf, Mayra Guerrero, Guy Reeder, Mackram Eleid, Charanjit S. Rihal, Jeremy Thaden
Journal: Journal of the American College of Cardiology (2020)
Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum
Authors: B. Solomon, V. Gregorc, F. Taguchi, K. Kasahara, M. Nishio, H. Roder, F. R. Hirsch, M. W. Duncan, P. A. Bunn, D. P. Carbone
Journal: Journal of Clinical Oncology (2006)

7004 Background: Assessment of epidermal growth factor receptor (EGFR) gene copy number, mutational status, and protein levels may predict response and possibly survival following treatment with EGFR tyrosine kinase inhibitors, but all these methods require tumor tissue, highlighting the need for a non-invasive predictive test. We evaluated the ability of MALDI-TOF MS profiling of serum to predict which patients (Pts) with NSCLC were likely to benefit from gefitinib treatment. Methods: Serum from Pts with NSCLC, collected prior to treatment with gefitinib, was subjected to MALDI-TOF MS using Voyager DE-STR or DE-PRO instruments. Replicate mass spectra obtained at two institutions were submitted to a third party for processing (background subtraction, noise estimation, normalization, spectral alignment and peak identification) and selection of discriminating mass/charge (m/z) values from a training cohort of 70 Caucasian Pts. The predictive capability of the profile was then assessed in independent cohorts of NSCLC Pts. Results: Intra- and inter- laboratory reproducibility of MALDI spectra were excellent. A set of 11 m/z values (mass range 5 - 12.5 kDa) predictive of clinical benefit were identified in the training cohort and confirmed by leave-one-out cross validation. Spectra from 19/70 Pts in the training cohort were unclassifiable. For the remaining 51 Pts the algorithm discriminated groups more or less likely to benefit with respect to time to progression (median 3.0 vs. 1.5 mo., p = 0.0325) and overall survival (median 14.6 vs. 2.3 mo., p = 0.0128). Validation was performed in an independent cohort consisting of serum from 69 Japanese Pts. Spectra from 13/69 Pts were unclassifiable. For the remaining 56 Pts it was possible to identify a group with superior time to progression (median 14.8 vs. 2.1 mo., p = 0.0012) and overall survival (median 19.1 vs. 7.9 mo., p = 0.0102). Conclusions: MALDI-TOF MS of pretreatment serum may aid with the identification of subsets of NSCLC Pts that will benefit from treatment with gefitinib. This algorithm is currently being evaluated in an expanded cohort of Pts receiving gefitinib treatment and in Pts treated with erlotinib. [Table: see text]
NON INVASIVE DETECTION OF ACCELERATED STENOTIC FLOW IN THE ENTIRE LEFT ANTERIOR DESCENDING CORONARY ARTERY PROVIDES INSIGHT INTO THE CAUSES OF IMPAIRED CORONARY FLOW RESERVE: A STUDY CONDUCTED WITH ENHANCED TRANSTHORACIC CONVERGENT COLOR DOPPLER ECHOCARDIOGRAPHY
Authors: Carlo Caiati, Mario Lepera, Paolo Pollice, Stefano Favale
Journal: Journal of the American College of Cardiology (2020)
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
Authors: Vinay K Puduvalli, Jing Wu, Ying Yuan, Terri S Armstrong, Elizabeth Vera, Jimin Wu, Jihong Xu, Pierre Giglio, Howard Colman, Tobias Walbert, Jeffrey Raizer, Morris D Groves, David Tran, Fabio Iwamoto, Nicholas Avgeropoulos, Nina Paleologos, Karen Fink, David Peereboom, Marc Chamberlain, Ryan Merrell, Marta Penas Prado, W K Alfred Yung, Mark R Gilbert
Journal: Neuro-Oncology (2020)

Bevacizumab has promising activity against recurrent glioblastoma (GBM). However, acquired resistance to this agent results in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibitor with anti-angiogenic effects, would prevent acquired resistance to bevacizumab.This multicenter phase II trial used a Bayesian adaptive design to randomize patients with recurrent GBM to bevacizumab alone or bevacizumab plus vorinostat with the primary endpoint of progression-free survival (PFS) and secondary endpoints of overall survival (OS) and clinical outcomes assessment (MD Anderson Symptom Inventory Brain Tumor module [MDASI-BT]). Eligible patients were adults (≥18 y) with histologically confirmed GBM recurrent after prior radiation therapy, with adequate organ function, KPS ≥60, and no prior bevacizumab or HDAC inhibitors.Ninety patients (bevacizumab + vorinostat: 49, bevacizumab: 41) were enrolled, of whom 74 were evaluable for PFS (bevacizumab + vorinostat: 44, bevacizumab: 30). Median PFS (3.7 vs 3.9 mo, P = 0.94, hazard ratio [HR] 0.63 [95% CI: 0.38, 1.06, P = 0.08]), median OS (7.8 vs 9.3 mo, P = 0.64, HR 0.93 [95% CI: 0.5, 1.6, P = 0.79]) and clinical benefit were similar between the 2 arms. Toxicity (grade ≥3) in 85 evaluable patients included hypertension (n = 37), neurological changes (n = 2), anorexia (n = 2), infections (n = 9), wound dehiscence (n = 2), deep vein thrombosis/pulmonary embolism (n = 2), and colonic perforation (n = 1).Bevacizumab combined with vorinostat did not yield improvement in PFS or OS or clinical benefit compared with bevacizumab alone or a clinical benefit in adults with recurrent GBM. This trial is the first to test a Bayesian adaptive design with adaptive randomization and Bayesian continuous monitoring in patients with primary brain tumor and demonstrates the feasibility of using complex Bayesian adaptive design in a multicenter setting.
Life expectancy (LE) and the receipt of conservative versus active treatment in men with prostate cancer (CaP): A population-based study.
Authors: Trevor Joseph Royce, Jonathan Todd, William A. Stokes, Ian M. Allen, Ronald C. Chen
Journal: Journal of Clinical Oncology (2012)

6032 Background: Prostate-specific antigen (PSA) screening increases the diagnosis of low-risk and potentially clinically insignificant CaP, which raises concern for possible overtreatment. The National Comprehensive Cancer Network (NCCN) guidelines recommend surveillance (conservative management) for patients with less than 10 years LE diagnosed with low-risk cancer. In contrast, NCCN recommends active treatment for high-risk CaP, the most aggressive form of this disease, irrespective of LE. We examine patterns of care in CaP patients in the Surveillance, Epidemiology and End Results (SEER) registry by LE. Methods: 152,578 men with non-metastatic CaP diagnosed from 2004-8 were included. Gleason, PSA, and clinical stage were used for risk-categorization per D’Amico criteria. The sample was dichotomized into men 76 years and younger (who have an average LE of 10 years or more based on the US Social Security Administration actuarial period life tables) vs. 77 years and older (less than 10 years average LE). Logistic regression models examined factors associated with each treatment modality. Results: 56% of patients age 77 and older with low-risk CaP received conservative management, and 44% active treatment (Table). However, conservative management was just as common in older patients with high-risk cancer (62%); 21% of younger patients with high-risk CaP also received conservative management. Multivariable analysis showed decreased use of conservative management over time in older patients (OR 0.78 for 2008 vs. 2004, 95%CI 0.71-.86, p&lt;.001). African American race, being unmarried, and older age were also significantly associated with conservative management. Conclusions: There may be overtreatment of low-risk CaP patients age 77 and older, which is worsening in recent years. Correspondingly, there appears to be undertreatment of elderly patients with high-risk CaP, the most aggressive form of this disease. [Table: see text]
HEALTHCARE UTILIZATION IN PEDIATRIC PATIENTS WITH MUSCULAR DYSTROPHY IN THE UNITED STATES
Authors: Jonathan Edelson, Susan Matesanz, Katherine Iacobellis, Erika Mejia, Joseph Rossano, Matthew J. O'Connor, Danielle Burstein, John Brandsema, Heather Griffis, Oluwatimilehin Okunowo, Kimberly Lin
Journal: Journal of the American College of Cardiology (2020)
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
Authors: Hong Liu, Xinwei Kuang, Yongchang Zhang, Youqiong Ye, Jialu Li, Long Liang, Zuozhong Xie, Liang Weng, Jia Guo, Hui Li, Fangyu Ma, Xiaodan Chen, Shuang Zhao, Juan Su, Nong Yang, Fang Fang, Yang Xie, Juan Tao, Jianglin Zhang, Mingliang Chen, Cong Peng, Lunquan Sun, Xin Zhang, Jing Liu, Leng Han, Xiaowei Xu, Mien-Chie Hung, Xiang Chen
Journal: Cancer Cell (2020)
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial
Authors: Madeleine T King, Emma K Link, Tim J Whelan, Ivo A Olivotto, Ian Kunkler, Antonia Helen Westenberg, Guenther Gruber, Penny Schofield, Boon H Chua, Boon H Chua, Claire Phillips, Guy Bryant, Helen Westenberg, Om Pra-Kesh Purohit, Verity Ahern, Peter Graham, Mohamed Akra, Orla McArdle, Peter O'Brien, Jane Ludbrook, Jennifer Harvey, John H Maduro, Isabelle Gabelle-Flandin, Carine Kirkove, Carolyn Bedi, Joseph Martin, Tony Vu, Theirry Muanza, Anthony Neal, Adel Courdi, Juliette Thariat, Eileen Rakovitch, Laurien Daniels, Marjan van Hezewijk, Wlasyslawa Cwajna, Adelheid Roelstraete, Angela van Baardwijk, Nicola Russel, Anne Koch, Jennifer Croke, Imogen Locke, Peter Jeal, Quenten Walker, Kandeepeepan Thuraisingham, Anupam Chauduri, David Joseph, Mandy Taylor, Sabine Vanderkam, Tony Woo, Johann Tang, Michael Yassa, Elaine Wai, Susan Hewitt, Shazia Mahmood, Jennifer Gilmore, Bolante Ofi, Amit Bahl, Olga Vujovic, Edward Yu, Duc Le, Iwa Kong, Alan Nichol, Nina Bijker, Geoff Delaney, Malcolm Feigen, Adeline Lim, Michael Chao, Margaret Latham, Hafiz Algurafi, Christoph Tausch, Eric Khoo, Sam Leung, Karen Taylor, Sasha Senthi, Andrea Stevens, Abhro Chaudhuri, Susan Cleator, Adrian Murray Brunt, Scott Babington, David Christie, Daniel Zwahlen, Ulrich Schratzenstaller, Laurence Masson, Nicola Storey, Eshwar Kumar, Liz Sherwin, Reinhilde Weytjens, Sharma Ravi, Patricia Lawton, Ruth Angell, Glenys Round, Angela Allen, Ziad Thotathil, Margaret Anthes, Christiane Reuter, Laura Pettit, Laura Pettit, Yvonne Zissiadis, Christine Elder, Antoinette Verbeek-de Kanter, Andree Lirette, Ludwig Plasswilm, David Spooner, Fiona Hoar, Islam Mohamed, Kristina Lossl, Vivienne Loo, Antonella Richetti, Tamasin Evans, Aisling Hennessy, Medhat El-Mallah, Marketa Skala, Raef Awad, Isabelle Germain, Carine Mitine, Hilde Van Parijs, Mark Churn, Nawaz Walji, Michael Francis, Karin Stellamans, Gunther Gruber, Giovanni Ivaldi, Abdulla Alhasso, Lizbeth Kenny, Ken Tiver, Matthew Griffin, Gillian Lamoury, Marco Trovo, Hafiz Algufarfi, Nawaz Walji, Minjae Lah, David Christie, Abdulla Alhasso, Scott Carruthers, George Papadatos, Gabriel Paardekooper, Abhro Chaudhuri, Mojca Persic, Bernadette Lavery
Journal: The Lancet Oncology (2020)
DELAYED NEED FOR PERMANENT PACEMAKER IMPLANTATION AFTER TAVR HOSPITAL DISCHARGE INSIGHTS FROM THE BRADY-TAVR STUDY
Authors: Khaldoun G. Tarakji, Divyang Patel, Amar Krishnaswamy, Ayman Hussein, Walid I. Saliba, Jose Luis Navia, Kathy Wolski, Lars G. Svensson, Oussama Wazni, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
Tuberculosis — United States, 2019
Authors: Noah G. Schwartz, Sandy F. Price, Robert H. Pratt, Adam J. Langer
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Since 1989, the United States has pursued a goal of eliminating tuberculosis (TB) through a strategy of rapidly identifying and treating cases and evaluating exposed contacts to limit secondary cases resulting from recent TB transmission (1).This strategy has been highly effective in reducing U.S. TB incidence (2), but the pace of decline has significantly slowed in recent years (2.2% average annual decline during 2012-2017 compared with 6.7% during 2007-2012) (3).For this report, provisional 2019 data reported to CDC's National Tuberculosis Surveillance System were analyzed to determine TB incidence overall and for selected subpopulations and these results were compared with those from previous years.During 2019, a total of 8,920 new cases were provisionally reported in the United States, representing a 1.1% decrease from 2018.*TB incidence decreased to 2.7 cases per 100,000 persons, a 1.6% decrease from 2018.Non-U.S.-born persons had a TB rate 15.5 times greater than the rate among U.S.-born persons.The U.S. TB case count and rate are the lowest ever reported, but the pace of decline remains slow.In recent years, approximately 80% of U.S. TB cases have been attributed to reactivation of latent TB infection (LTBI) acquired years in the past, often outside the United States (2).An expanded TB elimination strategy for this new decade should leverage existing health care resources, including primary care providers, to identify and treat persons with LTBI, without diverting public health resources from the continued need to limit TB transmission within the United States.Partnerships with health care providers, including private providers, are essential for this strategy's success.Health departments in the 50 U.S. states and the District of Columbia (DC) report all TB cases that meet the Council of State and Territorial Epidemiologists' surveillance case definition † to CDC.Reports include patient demographics, clinical features, and medical and social risk factors.Self-reported race/ ethnicity data are collected and reported following federal standards; Hispanics/Latinos can be of any race, and all other reported race categories are non-Hispanic/Latino.The U.S. Census Bureau defines a U.S.-born person as one born in the United States or a U.S. territory or born abroad to a U.S. citizen parent.Rates (cases per 100,000 persons) were calculated for the United States and administrative divisions (i.e., the 50 states, DC, and census divisions) using midyear U.S. * This report is limited to National Tuberculosis Surveillance System case reports verified as of March 3, 2020.Updated
PREVALENCE OF CONGENITAL HEART DEFECTS AMONG 1- TO 64- YEAR-OLDS RECEIVING HEALTHCARE AT FIVE U.S. SITES, 2011-2013
Authors: Jill Glidewell, Sherry Farr, Karrie Downing, Amber Khanna, Cheryl Raskind-Hood, Wendy Book, Lorenzo Botto, Marcia Feldkamp, Tiffany Riehle-Colarusso, Kristin Sommerhalter, Aida Soim, Alfred D'Ottavio, Jennifer Li, Tessa Crume
Journal: Journal of the American College of Cardiology (2020)
LONG-TERM OUTCOMES FOLLOWING STENT IMPLANTATION IN PATIENTS WITH VERSUS WITHOUT PRIOR PCI: AN INDIVIDUAL PATIENT-DATA POOLED ANALYSIS OF 20 RANDOMIZED CONTROLLED TRIALS
Authors: Mayank Yadav, Sorin J. Brener, Gary Mintz, Ajay Kirtane, Philippe Genereux, Mahesh Madhavan, Bjorn Redfors, Mengdan Liu, Pieter Smits, Clemens von Birgelen, Patrick Serruys, Martin Leon, Gregg Stone
Journal: Journal of the American College of Cardiology (2020)
1000 CONSECUTIVE PATIENTS EVALUATED FOR SAFETY AND EFFICACY: A FOCUSED STUDY OF PROHIBITED DEVICES IN THE MRI ENVIRONMENT
Authors: Robert W.W. Biederman, Loretta Gevenosky, Huma Samar, Ronald Williams, Richard Lombardi, Moneal Shah, Victor Farah, Francesco Mangini, Christopher Bonnet, Mark Doyle
Journal: Journal of the American College of Cardiology (2020)
Budget 2020: pension changes mean most doctors won’t be penalised for extra work
Authors: Adrian O’Dowd
Journal: BMJ (2020)

Most doctors will no longer be unfairly out of pocket for doing extra work, after the government pledged to increase the threshold income at which clinicians’ tax-free pension allowance is tapered.

The threshold income is being raised from £110 000 (€125 000; $140 000) to £200 000—a move announced on 11 March as part of the government’s new budget.1 The chancellor, Rishi Sunak, unveiled various financial changes designed to help the NHS in the long and short term, including a £5bn covid-19 response fund to help the health service deal with the outbreak.2

Regarding the change to pension arrangements, Sunak said, “To support the delivery of public services, particularly in the NHS, the two tapered annual allowance thresholds will each be raised by £90 000. This means that …
Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101–9
Authors: Charalampos Fragkoulis, Georgios Papadopoulos, Konstantinos Ntoumas
Journal: European Urology (2020)
USE OF MACHINE LEARNING METHODOLOGY TO FIND PREDICTORS OF ALL-CAUSE MORTALITY IN THE SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL (SPRINT)
Authors: Nuha Gani, Gauri Dandi, Zyannah Mallick, Adrita Ashraf, Victoria Xin, Ian Atkinson, Anwar Husain, Noah Hasan, Xin Tian, Colin Wu, Tejas Patel, Anna Kettermann, George Sopko, Carlos Cure, Gyorgy Csako, Danielle Jateng, Jerome Fleg, Victor Crentsil, Iffat Chowdhury, Keith Burkhart, Amit Dey, Eileen Navarro, Frank Pucino, Yves Rosenberg, Ahmed Hasan
Journal: Journal of the American College of Cardiology (2020)